Allianz Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Allianz Asset Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-11,394	Closed	-$366K	–	2712
2016 Q4	$366K	Hold	11,394	–	–	﹤0.01%	2428
2016 Q3	$562K	Sell	11,394 -683	-6%	-$28.4K	﹤0.01%	2341
2016 Q2	$512K	Hold	12,077	–	–	﹤0.01%	2309
2016 Q1	$795K	Sell	12,077 -226	-2%	-$11.8K	﹤0.01%	2159
2015 Q4	$778K	Hold	12,303	–	–	﹤0.01%	2069
2015 Q3	$823K	Hold	12,303	–	–	﹤0.01%	1909
2015 Q2	$1.2M	Buy	+12,303	New	+$1.17M	﹤0.01%	1892

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Allianz Asset Management's MACK Position: Q1 2017 in Review

Allianz Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2017, closing a stake of 11,394 shares — an estimated $366K sold.

Allianz Asset Management first reported a position in MACK in Q2 2015 and held it in 7 quarters. The position peaked at $1.2M in Q2 2015. 116 funds tracked by Wall St. Rank hold MACK as of Q1 2017.

Allianz Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Allianz Asset Management sold 11,394 Merrimack Pharmaceuticals, Inc. shares in Q1 2017, an estimated $366K.
Allianz Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2015 and held it in 7 quarters.
Allianz Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $1.2M in Q2 2015.
116 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2017.

Based on Allianz Asset Management's 13F filing for Q1 2017, filed 15 May 2017.